BiomX to Present at the Cantor Fitzgerald Global Healthcare Conference

NESS ZIONA, Israel, Sept. 30, 2019 /PRNewswire/ — BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced that BiomX’s Chief Executive Officer, Jonathan Solomon, will present at the Cantor Fitzgerald Global Healthcare Conference in New York on Wednesday, October 2nd, at 8:55am ET.

A webcast of the presentation will be available on the News and Events page of the company’s website at http://www.biomx.com/news/. A replay of the webcast will be available approximately two hours after the event and archived on the website for 90 days.

About BiomX

BiomX is a preclinical stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

www.biomx.com

On July 17th, 2019 BiomX announced that it has entered into a definitive agreement for a business combination with Chardan Healthcare Acquisition Corp. (NYSE: CHAC, “CHAC”), a special purpose acquisition company (“SPAC”) sponsored by affiliates of Chardan Capital Markets LLC (“Chardan”).

Media contact
MacDougall
Shai Biran, Ph.D.
Direct: +1-781-235-3060
sbiran@macbiocom.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biomx-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300926579.html

SOURCE BiomX Ltd.

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

2 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

3 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

3 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

4 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

6 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

6 hours ago